Murphy B G, Mok M Y, York D, Rebhun R, Woolard K D, Hillman C, Dickinson P, Skorupski K
Department Pathology, University of California, Davis, School of Veterinary Medicine, Microbiology and Immunology, Davis, CA, 95618, USA.
Department of Surgical and Radiological Sciences, Davis, CA, 95618, USA.
BMC Vet Res. 2017 Jun 20;13(1):189. doi: 10.1186/s12917-017-1113-5.
Osteosarcoma (OSA) is a common malignant bone tumor of large breed dogs that occurs at predictable anatomic sites. At the time of initial diagnosis, most affected dogs have occult pulmonary metastases. Even with aggressive surgical treatment combined with chemotherapy, the majority of dogs diagnosed with OSA live less than 1 year from the time of diagnosis. The ability to identify canine OSA cases most responsive to treatment is needed. In humans, OSA is also an aggressive tumor that is histologically and molecularly similar to canine OSA. The expression of the tumor suppressor gene product P16 by human OSA tissue has been linked to a favorable response to chemotherapy.
We identified an antibody that binds canine P16 and developed a canine OSA tissue microarray in order to test the hypothesis that P16 expression by canine OSA tissue is predictive of clinical outcome following amputation and chemotherapy. Although statistical significance was not reached, a trend was identified between the lack of canine OSA P16 expression and a shorter disease free interval.
The identification of a molecular marker for canine OSA is an important goal and the results reported here justify a larger study.
骨肉瘤（OSA）是大型犬常见的恶性骨肿瘤，发生于可预测的解剖部位。在初次诊断时，大多数患病犬已有隐匿性肺转移。即使采用积极的手术治疗并联合化疗，大多数被诊断为骨肉瘤的犬从诊断之时起存活时间不足1年。因此需要具备识别对治疗反应最佳的犬骨肉瘤病例的能力。在人类中，骨肉瘤也是一种侵袭性肿瘤，在组织学和分子水平上与犬骨肉瘤相似。人类骨肉瘤组织中肿瘤抑制基因产物P16的表达与化疗的良好反应相关。
我们鉴定出一种可与犬P16结合的抗体，并制作了犬骨肉瘤组织微阵列，以检验犬骨肉瘤组织中P16表达可预测截肢及化疗后临床结局这一假设。尽管未达到统计学显著性，但在犬骨肉瘤P16表达缺失与较短的无病间期之间发现了一种趋势。
鉴定犬骨肉瘤的分子标志物是一个重要目标，此处报告的结果证明有必要开展更大规模的研究。
